Drugs / Xenon-129
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06012500 | Apr 2022 → Dec 2026 expected | interstitial lung disease | Children's Hospital Medical Center, Cincinnati | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03331302 | Sep 2018 → Jun 2020 overdue | chronic obstructive pulmonary disease | University of Virginia | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02740868 Comparator | Aug 2015 → Dec 2026 expected | asthma, cystic fibrosis | The Hospital for Sick Children | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xenon-129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06012500 ↗ |
| Modality | Diagnostic / imaging agent | “xenon-129 which is used as a contrast agent for lung imaging” NCT02740868 ↗ |
| Route | Inhaled | “Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging” NCT02740868 ↗ |